Before offering PrEP (preexposure prophylaxis) for HIV with emtricitabine/tenofovir, which test result must be documented?

In the context of initiating PrEP with emtricitabine/tenofovir for HIV prevention, it is essential to document kidney function tests prior to starting treatment. Specifically, the relevant test is the serum creatinine level, which helps assess renal function, as the drug can have nephrotoxic effects. Monitoring kidney function is crucial because any significant impairment could increase the risk of adverse effects from the medication.

While liver enzymes, syphilis screening, and CD4 count are important components of comprehensive HIV care and management, they do not take precedence in the initial evaluation for PrEP. Liver function may affect treatment options, syphilis screening helps to identify co-infections that need treatment, and CD4 counts are used to assess the immune status of those already living with HIV rather than for those at risk for HIV who are considering PrEP. Therefore, ensuring that patients have adequate kidney function is the priority before starting PrEP therapy.